C. Rovirosa

VLP-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice

This study develops a neoantigen selection pipeline and a VLP-based vaccine platform to enhance immunogenicity and antitumor activity in mice.

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

The characteristics of the HIV-1 Env glycoprotein contribute to viral pathogenesis

This study examines how HIV-1 Env glycoprotein characteristics correlate with viral pathogenesis by comparing functional and sequence features across different clinical progression groups.

Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.

The paper assesses how prior SARS-CoV-2 infection affects B.1.1.7 cross-neutralization in vaccinated individuals, finding that previously infected individuals show equivalent neutralization against B.1.1.7 compared to the Wuhan strain.

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.